Skip to main content
Steven Rowe, MD, Pulmonology, Birmingham, AL, Children's of Alabama

StevenMRoweMD

Pulmonology Birmingham, AL

Critical Care Medicine, Pleural Disease

Assistant Professor, Medicine, University of Alabama School of Medicine

Dr. Rowe is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Rowe's full profile

Already have an account?

Education & Training

  • University of Alabama Hospital
    University of Alabama HospitalFellowship, Pulmonary Disease and Critical Care Medicine, 2002 - 2006
  • University of Alabama Hospital
    University of Alabama HospitalResidency, Internal Medicine/Pediatrics, 1998 - 2002
  • Vanderbilt University School of Medicine
    Vanderbilt University School of MedicineClass of 1998

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 1999 - 2022
  • American Board of Internal Medicine Critical Care Medicine
  • American Board of Internal Medicine Pulmonary Disease

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial  
    Steven Rowe, MD, Dove Press
  • Ivacaftor Improves Rhinologic, Psychologic, and Sleep‐Related Quality of Life in G551D Cystic Fibrosis Patients  
    Bradford A Woodworth, Justin McCormick, Steven M Rowe, Brooks Lampkin, International Forum of Allergy & Rhinology
  • Non-Obstructive Vas Deferens and Epididymis Loss in Cystic Fibrosis Rats  
    J S Hong, E J Sorscher, S M Rowe, ScienceDirect
  • Join now to see all

Press Mentions

  • Synspira Announces Data for Lead Candidate at the 31
    Synspira Announces Data for Lead Candidate at the 31November 2nd, 2017
  • ProQR R&D Day Highlights Progress on Pipeline and Introduces Axiomer®, a Novel Proprietary RNA Technology
    ProQR R&D Day Highlights Progress on Pipeline and Introduces Axiomer®, a Novel Proprietary RNA TechnologyJune 15th, 2017
  • Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients
    Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis PatientsSeptember 13th, 2018
  • Join now to see all

Grant Support

  • Clinical And Translational CoreNational Institute Of Diabetes And Digestive And Kidney Diseases2012
  • Molecular Pathogenesis And Phenotype Of Acquired CFTR Dysfunction In COPDNational Heart, Lung, And Blood Institute2011–2012
  • Mechanistic Basis Underlying Protein Repair Of CFTR Nonsense MutationsNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2010
  • Clinical And Mechanistic Features Of Premature Termination Codon SuppressionNational Institute Of Diabetes And Digestive And Kidney Diseases2007–2010
  • Premature Termination Codon SuppressionNational Institute Of Diabetes And Digestive And Kidney Diseases2006

Hospital Affiliations